Table 1. Baseline demographics and oncological history.
|
BI 2536 schedule
|
||
|---|---|---|
| Characteristic a | 200 mg, day 1 ( n =43) | 60 mg, days 1–3 ( n =43) |
| Median age, years | 66.0 | 64.0 |
| Male, n (%) | 30 (69.8) | 29 (67.4) |
| Median weight, kg | 76.25 | 75.00 |
| Karnofsky performance status, n (%) | ||
| 70 | 2 (4.7) | 2 (4.7) |
| 80 | 7 (16.3) | 7 (16.3) |
| 90 | 17 (39.5) | 13 (30.2) |
| 100 | 17 (39.5) | 21 (48.8) |
| Mean time from diagnosis, years (range) | 0.21 (0–2.1) | 0.11 (0–1.2) |
| Ductal adenocarcinoma, n (%) | 35 (81) | 40 (93) |
| Region of primary site, n (%) | ||
| Head | 28 (65) | 22 (51) |
| Tail | 9 (21) | 13 (30) |
| Corpus | 5 (12) | 6 (14) |
| Unknown | 1 (2) | 2 (5) |
| Differentiation grade, n (%) | ||
| Well differentiated | 1 (2) | 2 (5) |
| Moderately differentiated | 22 (51) | 21 (49) |
| Poorly differentiated | 10 (23) | 11 (26) |
| Not specified | 9 (21) | 9 (21) |
| Unknown | 1 (2) | 0 (0) |
| Stage at screening, n (%)a | ||
| 0 | 1 (2) | 0 (0) |
| I | 0 (0) | 1 (2) |
| IIA | 1 (2) | 0 (0) |
| IIB | 1 (2) | 1 (2) |
| IIIA | 2 (5) | 1 (2) |
| IIIB | 1 (2) | 1 (2) |
| IV | 37 (86) | 39 (91) |
a
Because of rounding, percentages may not add up to 100%.